Project Grant R01CA278744
Award Date
3/1/24
Completion Date
2/28/29
Dollars Obligated
$463K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $215,311 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on developing and evaluating antibody-drug conjugates (ADCs) targeting the GPR56 receptor for the treatment of triple-negative breast cancer (TNBC). The key products and services to be delivered under this 2-year grant include: Generation and testing of novel GPR56-targeted ADCs with different cytotoxic drugs to identify lead candidates with high specificity and potent...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop novel therapies for advanced metastatic triple-negative breast cancer (TNBC). The $622,329 award to Virginia Commonwealth University aims to modulate the growth, progression, and metastasis of TNBC by inhibiting the MDA-9 protein. Key objectives include: 1) formulating an MDA-9 inhibitor called PDZ1I for clinical use and characterizing its effects on the immune...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $822,412 to The Leland Stanford Junior University to establish the [18F]HGTS13 PET radiotracer as a non-invasive imaging marker for monitoring drug-induced cancer ferroptosis in cell culture and preclinical models. The goals are to: 1) demonstrate the relationship between [18F]HGTS13 uptake and sensitivity to ferroptosis in vitro and in vivo; 2) test [18F]HGTS13's...
The National Cancer Institute (NCI) awarded a $148,568 Project Grant (CFDA 93.398 - Cancer Research Manpower) to The Leland Stanford Junior University on December 17, 2024. The grant, titled "INTEGRATING HIGHLY MULTIPLEXED IMMUNOFLUORESCENCE WITH LABEL-FREE 2D HYPERSPECTRAL CHEMICAL IMAGING TO INTERROGATE THE COLORECTAL CANCER TUMOR-INVASIVE FRONT," supports research aimed at understanding colorectal cancer biology through the integration of advanced imaging techniques. The project...
This Project Grant award from the National Cancer Institute, funded under the Cancer Treatment Research program (CFDA 93.395), is focused on developing peptide drug conjugates to treat triple negative breast cancer (TNBC). The goal is to create novel peptide-based drug delivery systems to improve the efficacy of chemotherapies for this aggressive form of breast cancer. The $530,358 award to Molecular Theranostics LLC will support two key objectives: 1) synthesizing and characterizing a peptide...
The National Cancer Institute (NCI) awarded a $432,837 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to The Leland Stanford Junior University. The grant, with a start date of July 1, 2024 and an end date of December 31, 2024, will fund research to: (1) define the most therapeutically relevant CAR T cell subsets in patients with large B cell lymphoma (LBCL), and (2) overcome an immune suppression mechanism of resistance to CAR T cell therapy for LBCL. The...
This federal Cooperative Agreement award from the Department of the Interior's Interior Business Center under the Advanced Research Projects Agency for Health (ARPA-H) program (CFDA 93.384) provides $11,574,776.00 to The Leland Stanford Junior University to develop personalized radiopharmaceuticals for PET imaging-based diagnosis and targeted cancer treatment. The key products include: A tabletop device capable of producing small doses of radiopharmaceuticals on-site at patient clinics through a...
The Leland Stanford Junior University was awarded a $4.72 million Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The grant will fund research from March 2021 through March 2025 relating the interplay of tumor function and host response to clinical outcome in triple negative breast cancer. Through this award, Stanford University researchers will investigate medical solutions for breast cancer on the battlefield and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $676,567 to The Regents of the University of California, San Francisco (UCSF) to systematically evaluate a transforming growth factor beta (TGFβ) targeted theranostic radiopharmaceutical therapy (RPT) approach across preclinical cancer models. The 5-year project, which began on December 16, 2024, aims to leverage UCSF's deep understanding of TGFβ biology and the clinical...
This Project Grant award of $781,436.00 from the National Cancer Institute (NCI) under the Cancer Treatment Research Federal Grant Program (CFDA 93.395) aims to optimize anti-N-methyl-D-aspartate receptor (NMDAR) antibodies for the treatment of triple-negative breast cancer (TNBC). The key products and services to be delivered under this 5-year award, which began on April 14, 2025, include: Establishing an orthotopic mouse model of NMDAR-positive TNBC to evaluate NMDAR-targeting antibody...